MyoKardia (MYOK) announced Monday that its experimental drug mavacamten demonstrated statistically significant improvements in blood flow and aerobic capacity in patients with an inherited form of heart disease in a small, mid-stage clinical trial.
Eight of the 10 patients who completed the study achieved improvement in blood flow to a level where they no longer met the threshold for being diagnosed with their disease — obstructive hypertrophic cardiomyopathy, or HCM.
About the Author Reprints
Pts with HCM that had operation for it got rid of obstruction but continue to have VO2 problem. Who can I talk to about likely taking them as stage 2-3?